<p>Simplify Asset Management Inc. 在最近向证券交易委员会（SEC）提交的 13F 文件中披露，在第三季度将其在再生元制药公司（NASDAQ:REGN - 免费报告）的持股增加了 251.1%。该机构投资者在此期间额外购买了 9,284 股后，持有该生物制药公司的 12,981 股股票。再生元制药占 Simplify Asset Management Inc. 持有股票的 0.1%，使其成为该公司第 21 大持股。根据其最近向证券交易委员会（SEC）提交的文件，Simplify Asset Management Inc. 在再生元制药的持股价值为 7,299,000 美元。</p>
<ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也增加或减少了在 REGN 的持股。PGGM Investments 在第二季度将其在再生元制药的持股增加了 159.7%。PGGM Investments 目前持有 84,397 股该生物制药公司的股票，价值 44,308,000 美元，此前在上个季度额外购买了 51,900 股。Founders Capital Management LLC 在第二季度将其在再生元制药的持股增加了 7.0%。Founders Capital Management LLC 目前持有 8,274 股该生物制药公司的股票，价值 4,344,000 美元，此前在此期间额外购买了 538 股。Sepio Capital LP 在第一季度将其在再生元制药的持股增加了 33.1%。Sepio Capital LP 目前持有 3,389 股该生物制药公司的股票，价值 2,150,000 美元，此前在上个季度购买了 842 股。Generate Investment Management Ltd 在第二季度获得了再生元制药的新头寸，价值 6,300,000 美元。最后，Osaic Holdings Inc. 在第二季度将其在再生元制药的持股增加了 55.2%。Osaic Holdings Inc. 目前持有 17,068 股该生物制药公司的股票，价值 9,607,000 美元，此前在上个季度购买了 6,073 股。83.31% 的股票目前由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>几家研究公司最近对 REGN 发布了报告。加拿大皇家银行在 10 月 29 日的研究报告中将再生元制药的目标价从 704.00 美元上调至 708.00 美元，并给予该股票 &#34;行业表现&#34; 的评级。汇丰银行在 11 月 24 日的研究报告中开始覆盖再生元制药的股票。他们为该公司设定了 &#34;买入&#34; 评级和 255.00 美元的目标价。Weiss Ratings 在 12 月 22 日的研究报告中重新发布了对再生元制药的 &#34;持有 (c)&#34; 评级。Canaccord Genuity Group 在 12 月 4 日的报告中将再生元制药的目标价从 850.00 美元上调至 1,057.00 美元，并给予该公司 &#34;买入&#34; 评级。最后，富国银行在 12 月 10 日的研究报告中将再生元制药的目标价从 700.00 美元上调至 745.00 美元，并给予该公司 &#34;等权重&#34; 的评级。三位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，八位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，平均目标价为 779.45 美元。</p>
<ul>
<li>5 家医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p><strong>阅读我们关于 REGN 的最新报告</strong></p>
<h2>内部人士买卖</h2>
<p>在其他再生元制药的新闻中，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股该股票。这些股票以平均价格 654.27 美元出售，总价值为 4,252,755.00 美元。出售完成后，该董事持有 2,352 股公司的股票，价值 1,538,843.04 美元。这笔交易代表了他们持有股票的 73.43% 的减少。该出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。此外，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。这些股票以平均价格 651.43 美元出售，总交易额为 280,766.33 美元。交易完成后，副总裁持有 4,233 股公司的股票，价值 2,757,503.19 美元。这笔交易代表了他们持有股票的 9.24% 的减少。有关此出售的更多细节可在官方 SEC 披露中找到。7.02% 的股票由公司内部人士持有。</p>
<h2>再生元制药股价下跌 0.6%</h2>
<ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年飙升</li>
</ul>
<p>REGN 股票在周二开盘价为 780.50 美元。该公司的市值为 820.3 亿美元，市盈率为 18.69，PEG 比率为 2.26，贝塔值为 0.37。再生元制药公司 52 周低点为 476.49 美元，52 周高点为 792.77 美元。该公司的速动比率为 3.33，流动比率为 4.06，债务与股本比率为 0.09。该业务的 50 日简单移动平均为 707.58 美元，200 日简单移动平均为 612.72 美元。</p>
<p>再生元制药（NASDAQ:REGN - 获取免费报告）在 10 月 28 日最后发布了其财报。该生物制药公司报告本季度每股收益（EPS）为 11.83 美元，超出分析师一致预期的 9.73 美元，超出 2.10 美元。再生元制药的股本回报率为 13.76%，净利润率为 32.13%。该业务在本季度的收入为 37.5 亿美元，而分析师预期为 35.7 亿美元。在去年同期，该业务的每股收益为 12.46 美元。该公司的季度收入同比增长 0.9%。平均而言，股票研究分析师预计再生元制药公司本年度将发布 35.92 美元的每股收益。</p>
<h2>再生元制药分红公告</h2>
<p>该公司最近还披露了季度分红，分红于 12 月 5 日（星期五）支付。11 月 20 日（星期四）登记在册的股东获得每股 0.88 美元的分红。这相当于年化分红 3.52 美元，分红收益率为 0.5%。除息日为 11 月 20 日（星期四）。再生元制药的派息比率目前为 8.43%。</p>
<h2>再生元制药公司简介</h2>
<p>（免费报告）</p>
<p>再生元制药公司（Regeneron Pharmaceuticals, Inc.）纳斯达克代码：REGN，是一家总部位于纽约塔里敦的美国生物技术公司，成立于 1988 年。该公司专注于发现、开发、生产和商业化用于治疗严重医疗状况的药物。公司结合实验室研究、临床开发和内部生产，推进多种治疗领域的生物治疗管线。</p>
<p>再生元以其专有的药物发现技术而闻名，包括其 VelocImmune 平台，该平台用于生成完全人源的单克隆抗体。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过再生元制药</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>家族信托如何帮助保护你的财富</li>
<li>你的 “出生权索赔” 刚刚被激活</li>
<li>传奇投资者发出的令人不安的警告</li>
</ul>
<p><strong>想看看其他对 REGN 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取再生元制药公司（NASDAQ:REGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在再生元制药吗？</h2>
<p>在考虑再生元制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而再生元制药并不在名单上。</p>
<p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

再生元制药

<p>Simplify Asset Management Inc. 在第三季度将其在再生元制药的股份增加了 251.1%，目前持有 12,981 股，价值 730 万美元。其他机构投资者也增加了他们的持股。分析师对 REGN 的评级显示共识为 “适度买入”，平均目标价为 779.45 美元。最近的内部交易包括董事 Christine A. Poon 出售 6,500 股。REGN 股票开盘价为 780.50 美元，市值为 820.3 亿美元</p>

<p>Simplify Asset Management Inc. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 251.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,981 shares of the biopharmaceutical company's stock after acquiring an additional 9,284 shares during the period. Regeneron Pharmaceuticals accounts for 0.1% of Simplify Asset Management Inc.'s holdings, making the stock its 21st biggest holding. Simplify Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $7,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Simplify Asset Management Inc. 在最近向证券交易委员会（SEC）提交的 13F 文件中披露，在第三季度将其在再生元制药公司（NASDAQ:REGN - 免费报告）的持股增加了 251.1%。该机构投资者在此期间额外购买了 9,284 股后，持有该生物制药公司的 12,981 股股票。再生元制药占 Simplify Asset Management Inc. 持有股票的 0.1%，使其成为该公司第 21 大持股。根据其最近向证券交易委员会（SEC）提交的文件，Simplify Asset Management Inc. 在再生元制药的持股价值为 7,299,000 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. PGGM Investments increased its holdings in Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock valued at $44,308,000 after buying an additional 51,900 shares in the last quarter. Founders Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock worth $4,344,000 after acquiring an additional 538 shares during the period. Sepio Capital LP increased its stake in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after purchasing an additional 842 shares in the last quarter. Generate Investment Management Ltd acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $6,300,000. Finally, Osaic Holdings Inc. boosted its position in Regeneron Pharmaceuticals by 55.2% during the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company's stock worth $9,607,000 after purchasing an additional 6,073 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也增加或减少了在 REGN 的持股。PGGM Investments 在第二季度将其在再生元制药的持股增加了 159.7%。PGGM Investments 目前持有 84,397 股该生物制药公司的股票，价值 44,308,000 美元，此前在上个季度额外购买了 51,900 股。Founders Capital Management LLC 在第二季度将其在再生元制药的持股增加了 7.0%。Founders Capital Management LLC 目前持有 8,274 股该生物制药公司的股票，价值 4,344,000 美元，此前在此期间额外购买了 538 股。Sepio Capital LP 在第一季度将其在再生元制药的持股增加了 33.1%。Sepio Capital LP 目前持有 3,389 股该生物制药公司的股票，价值 2,150,000 美元，此前在上个季度购买了 842 股。Generate Investment Management Ltd 在第二季度获得了再生元制药的新头寸，价值 6,300,000 美元。最后，Osaic Holdings Inc. 在第二季度将其在再生元制药的持股增加了 55.2%。Osaic Holdings Inc. 目前持有 17,068 股该生物制药公司的股票，价值 9,607,000 美元，此前在上个季度购买了 6,073 股。83.31% 的股票目前由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research firms have recently issued reports on REGN. Royal Bank Of Canada lifted their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a &#34;sector perform&#34; rating in a research note on Wednesday, October 29th. HSBC started coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a &#34;buy&#34; rating and a $255.00 target price for the company. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 22nd. Canaccord Genuity Group increased their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 4th. Finally, Wells Fargo &amp; Company upped their price objective on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an &#34;equal weight&#34; rating in a research report on Wednesday, December 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $779.45.</p>
<div class="lb-trans"><p>几家研究公司最近对 REGN 发布了报告。加拿大皇家银行在 10 月 29 日的研究报告中将再生元制药的目标价从 704.00 美元上调至 708.00 美元，并给予该股票 &#34;行业表现&#34; 的评级。汇丰银行在 11 月 24 日的研究报告中开始覆盖再生元制药的股票。他们为该公司设定了 &#34;买入&#34; 评级和 255.00 美元的目标价。Weiss Ratings 在 12 月 22 日的研究报告中重新发布了对再生元制药的 &#34;持有 (c)&#34; 评级。Canaccord Genuity Group 在 12 月 4 日的报告中将再生元制药的目标价从 850.00 美元上调至 1,057.00 美元，并给予该公司 &#34;买入&#34; 评级。最后，富国银行在 12 月 10 日的研究报告中将再生元制药的目标价从 700.00 美元上调至 745.00 美元，并给予该公司 &#34;等权重&#34; 的评级。三位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，八位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，平均目标价为 779.45 美元。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p><strong>Read Our Latest Report on REGN</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 REGN 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company's stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company's stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他再生元制药的新闻中，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股该股票。这些股票以平均价格 654.27 美元出售，总价值为 4,252,755.00 美元。出售完成后，该董事持有 2,352 股公司的股票，价值 1,538,843.04 美元。这笔交易代表了他们持有股票的 73.43% 的减少。该出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。此外，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。这些股票以平均价格 651.43 美元出售，总交易额为 280,766.33 美元。交易完成后，副总裁持有 4,233 股公司的股票，价值 2,757,503.19 美元。这笔交易代表了他们持有股票的 9.24% 的减少。有关此出售的更多细节可在官方 SEC 披露中找到。7.02% 的股票由公司内部人士持有。</p>
</div><h2>Regeneron Pharmaceuticals Trading Down 0.6%</h2>
<div class="lb-trans"><h2>再生元制药股价下跌 0.6%</h2>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年飙升</li>
</ul>
</div><p>REGN stock opened at $780.50 on Tuesday. The company has a market cap of $82.03 billion, a price-to-earnings ratio of 18.69, a PEG ratio of 2.26 and a beta of 0.37. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $792.77. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $707.58 and a 200-day simple moving average of $612.72.</p>
<div class="lb-trans"><p>REGN 股票在周二开盘价为 780.50 美元。该公司的市值为 820.3 亿美元，市盈率为 18.69，PEG 比率为 2.26，贝塔值为 0.37。再生元制药公司 52 周低点为 476.49 美元，52 周高点为 792.77 美元。该公司的速动比率为 3.33，流动比率为 4.06，债务与股本比率为 0.09。该业务的 50 日简单移动平均为 707.58 美元，200 日简单移动平均为 612.72 美元。</p>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analysts' expectations of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 EPS. The company's revenue for the quarter was up .9% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.</p>
<div class="lb-trans"><p>再生元制药（NASDAQ:REGN - 获取免费报告）在 10 月 28 日最后发布了其财报。该生物制药公司报告本季度每股收益（EPS）为 11.83 美元，超出分析师一致预期的 9.73 美元，超出 2.10 美元。再生元制药的股本回报率为 13.76%，净利润率为 32.13%。该业务在本季度的收入为 37.5 亿美元，而分析师预期为 35.7 亿美元。在去年同期，该业务的每股收益为 12.46 美元。该公司的季度收入同比增长 0.9%。平均而言，股票研究分析师预计再生元制药公司本年度将发布 35.92 美元的每股收益。</p>
</div><h2>Regeneron Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>再生元制药分红公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.43%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，分红于 12 月 5 日（星期五）支付。11 月 20 日（星期四）登记在册的股东获得每股 0.88 美元的分红。这相当于年化分红 3.52 美元，分红收益率为 0.5%。除息日为 11 月 20 日（星期四）。再生元制药的派息比率目前为 8.43%。</p>
</div><h2>Regeneron Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>再生元制药公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.</p>
<div class="lb-trans"><p>再生元制药公司（Regeneron Pharmaceuticals, Inc.）纳斯达克代码：REGN，是一家总部位于纽约塔里敦的美国生物技术公司，成立于 1988 年。该公司专注于发现、开发、生产和商业化用于治疗严重医疗状况的药物。公司结合实验室研究、临床开发和内部生产，推进多种治疗领域的生物治疗管线。</p>
</div><p>Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.</p>
<div class="lb-trans"><p>再生元以其专有的药物发现技术而闻名，包括其 VelocImmune 平台，该平台用于生成完全人源的单克隆抗体。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Your “birthright claim” just got activated</li>
<li>Chilling warning from legendary investor</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过再生元制药</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>家族信托如何帮助保护你的财富</li>
<li>你的 “出生权索赔” 刚刚被激活</li>
<li>传奇投资者发出的令人不安的警告</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding REGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 REGN 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取再生元制药公司（NASDAQ:REGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在再生元制药吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑再生元制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而再生元制药并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Simplify Asset Management Inc. 增持了再生元制药公司（Regeneron Pharmaceuticals, Inc.）的股份